Celgene Revamps IO Deal With Emerging Biotech Sutro; Takeover Option Removed

Celgene and small Californian biotech Sutro have renovated their 2014 cancer drug discovery deal to grant Celgene worldwide rights to the first two products to emerge from the arrangement, and to lift restrictions on Sutro accessing public financial markets.